Graves病^131I治疗前和治疗一年中促甲状腺素受体抗体水平的动态变化

Dynamics of thyroid-stimulating hormone receptor antibody during one year after ^131I treatment of Graves＇ disease

对157例Graves病^131I门诊治疗的病例进行回顾性研究。按^131I治疗1年后甲状腺功能状态分成3组：缓解组（FT3、FT4正常）、部分缓解组（FT3、FT4未降至正常范围）、甲减组（FT3、FT4低于正常）。治疗前促甲状腺素受体抗体（TRAb）的阳性率为88．5％。^131I治疗后，TRAb在3。6个月时达高峰，之后逐渐下降。甲状腺重量、显著升高的TRAb（t〉405U／L）、FT3、FT4水平是评估预后的指标。

One hundred and fifty-seven patients with Graves＇ disease treated with ^131I from July 2001 to March 2003 were studied retrospectively. According to the thyroid function one year after ^131I therapy, the patients were divided into 3 groups ： remission group with normal FT3, FT4, partial remission group with above normal levels of FT3, FT4, and hypothyroid group with lowered levels of FT3 , FT4. Prior to ^131I treatment the thyroid-stimulating hormone receptor antibody （TRAb） was positive in 88.5% of the patients. After the therapy, TRAb levels rose transiently and reached the peak within 3-6 months and then dropped gradually thereafter. The weight of pretreatment thyroid, high levels of TRAb （≥ 405 U/L ） and FT3, FT4 were predictors for the outcome of treatment.